Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Importance: Limited data suggest that early palliative care (EPC) improves quality of life (QOL) and survival in patients with advanced cancer.

Objective: To evaluate whether comprehensive EPC improves QOL; relieves mental, social, and existential burdens; increases survival rates; and helps patients develop coping skills.

Design, Setting, And Participants: This nonblinded randomized clinical trial (RCT) recruited patients from 12 hospitals in South Korea from September 2017 to October 2018. Patients aged 20 years or older with advanced cancer who were not terminally ill but for whom standard chemotherapy has not been effective were eligible. Participants were randomized 1:1 to the control (receiving usual supportive oncological care) or intervention (receiving EPC with usual oncological care) group. Intention-to-treat data analysis was conducted between September and December 2022.

Interventions: The intervention group received EPC through a structured program of self-study education materials, telephone coaching, and regular assessments by an integrated palliative care team.

Main Outcomes And Measures: The primary outcome was the change in overall QOL score (assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care) from baseline to 24 weeks after enrollment, with evaluations also conducted at 12 and 18 weeks. Secondary outcomes were social and existential burdens (assessed with the McGill Quality of Life Questionnaire) as well as crisis-overcoming capacity and 2-year survival.

Results: A total of 144 patients (83 males [57.6%]; mean [SD] age, 60.7 (7.2) years) were enrolled, of whom 73 were randomized to the intervention group and 71 to the control group. The intervention group demonstrated significantly greater changes in scores in overall health status or QOL from baseline, especially at 18 weeks (11.00 [95% CI, 0.78-21.22] points; P = .04; effect size = 0.42). However, at 12 and 24 weeks, there were no significant differences observed. Compared with the control group, the intervention group also showed significant improvement in self-management or coping skills over 24 weeks (20.51 [95% CI, 12.41-28.61] points; P < .001; effect size = 0.93). While the overall survival rate was higher in the intervention vs control group, the difference was not significant. In the intervention group, however, those who received 10 or more EPC interventions (eg, telephone coaching sessions and care team meetings) showed a significantly increased probability of 2-year survival (53.6%; P < .001).

Conclusions And Relevance: This RCT demonstrated that EPC enhanced QOL at 18 weeks; however, no significant improvements were observed at 12 and 24 weeks. An increased number of interventions sessions was associated with increased 2-year survival rates in the intervention group.

Trial Registration: ClinicalTrials.gov Identifier: NCT03181854.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11310828PMC
http://dx.doi.org/10.1001/jamanetworkopen.2024.26304DOI Listing

Publication Analysis

Top Keywords

palliative care
16
intervention group
16
quality life
12
integrated palliative
8
patients advanced
8
advanced cancer
8
randomized clinical
8
clinical trial
8
epc improves
8
social existential
8

Similar Publications

Home parenteral nutrition (HPN) is a life-sustaining therapy traditionally used as a bridge to enteral autonomy or intestinal transplantation. Increasingly, it is used for intractable feeding intolerance (IFI), which can occur near the end of life (EOL) in children with severe neurological impairment (SNI). In these cases, HPN use differs from its historical role and requires tailored outpatient planning.

View Article and Find Full Text PDF

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.

Pharmacoecon Open

September 2025

Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.

Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.

View Article and Find Full Text PDF

Prospective validation of the Nottingham Hip Fracture Score for predicting 1-year mortality in a Spanish cohort.

Br J Anaesth

September 2025

Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca i Innovació en Ciències de la Vida i la Salut a la Catalunya Central (IrisCC), Vic, Barcelona, Spain; Department of Internal Medicine, Hospital d'Olot i comarcal de la Garrotxa, Olot, Girona, Spain; Faculty of Medicine, Univer

View Article and Find Full Text PDF

Introduction: One of the current challenges in Parkinson's disease (PD) and other movement disorders (MD) is how and when to apply palliative care. Aware of the scarce training and implementation of this type of approach, we propose some consensual recommendations for palliative care (PC) in order to improve the quality of life of patients and their environment.

Material And Methods: After a first phase of needs analysis through a survey carried out on Spanish neurologists and a review of the literature, we describe recommendations for action structured in: palliative care models, selection of the target population, when, where and how to implement the PC.

View Article and Find Full Text PDF

Management of dyspnea with high-flow nasal air or fan - a randomized controlled crossover trial.

J Pain Symptom Manage

September 2025

Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland and Department of Palliative Care Centre and Home Hospital Services, Tampere University Hospital, The Wellbeing Services County of Pirkanmaa, Finland.

Context: High-flow nasal therapy (HFNT) may relieve severe dyspnea, but its role compared to other treatment options in palliative care remains unclear.

Objectives: Assess the effect and feasibility of HFNT with air compared to fan therapy in relieving dyspnea among non-hypoxemic patients with incurable cancer.

Methods: This prospective, randomized, controlled, crossover trial compared airflow delivered by HFNT and fan.

View Article and Find Full Text PDF